Form 8-K - Current report:
SEC Accession No. 0001193125-26-299290
Filing Date
2026-07-09
Accepted
2026-07-09 09:31:32
Documents
11
Period of Report
2026-07-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fblg-20260702.htm   iXBRL 8-K 50698
2 EX-99.1 fblg-ex99_1.htm EX-99.1 17168
3 GRAPHIC img111178190_0.jpg GRAPHIC 18530
  Complete submission text file 0001193125-26-299290.txt   204848

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fblg-20260702.xsd EX-101.SCH 24859
14 EXTRACTED XBRL INSTANCE DOCUMENT fblg-20260702_htm.xml XML 4697
Mailing Address 9350 KIRBY DRIVE SUITE 300 HOUSTON TX 77054
Business Address 9350 KIRBY DRIVE SUITE 300 HOUSTON TX 77054 281-671-5150
FibroBiologics, Inc. (Filer) CIK: 0001958777 (see all company filings)

EIN.: 863329066 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41934 | Film No.: 261164259
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)